Caligan Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Caligan Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,000	Closed	-$159K	–	12
2022 Q4	$159K	Buy	+1,000	New	+$147K	0.13%	10

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Caligan Partners's JAZZ Position: Q1 2023 in Review

Caligan Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 1,000 shares — an estimated $159K sold.

Caligan Partners first reported a position in JAZZ in Q4 2022 and held it in 1 quarter. The position peaked at $159K in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Caligan Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Caligan Partners sold 1,000 Jazz Pharmaceuticals shares in Q1 2023, an estimated $159K.
Caligan Partners first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Caligan Partners's Jazz Pharmaceuticals position peaked at $159K in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Caligan Partners's 13F filing for Q1 2023, filed 15 May 2023.